Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

NARecruitingINTERVENTIONAL
Enrollment

920

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Atrial Fibrillation (AF)VTE
Interventions
OTHER

PAUSE Perioperative DOAC Management

PAUSE management is simple and easy to apply as patients having a high-bleed-risk surgery/neuraxial procedure interrupt DOACs for 2 days before and 2 days after surgery without heparin bridging or DOAC level testing.

OTHER

ASRA Perioperative DOAC Management

ASRA management is more complex, requiring 72-120 hours DOAC interruption and, in selected patients, pre-operative heparin bridging and DOAC level testing.

Trial Locations (14)

10305

NOT_YET_RECRUITING

Northwell Health System, New York

19107

NOT_YET_RECRUITING

Thomas Jefferson University Hospital, Philadelphia

48202

NOT_YET_RECRUITING

Henry Ford Health Care, Detroit

60201

NOT_YET_RECRUITING

North Shore University Health, Evanston

06106

NOT_YET_RECRUITING

Hartford Health Care, Hartford

02115

NOT_YET_RECRUITING

Brigham and Woman's Hospital, Boston

Unknown

NOT_YET_RECRUITING

University of Leuven, Leuven

NOT_YET_RECRUITING

Winnipeg Health Sciences Center, Winnipeg

NOT_YET_RECRUITING

Juravinski, Hamilton

NOT_YET_RECRUITING

L'Hospital Montfort, Ottawa

NOT_YET_RECRUITING

Toronto General Hospital, Toronto

NOT_YET_RECRUITING

University of Thessaly, Larissa

L8N 4A6

RECRUITING

St. Joesph's Healthcare, Hamilton

K1H 8L6

NOT_YET_RECRUITING

The Ottawa Hospital, Ottawa

All Listed Sponsors
lead

McMaster University

OTHER